Developments in targeted AML therapies: venetoclax, quizartinib & amp; gilteritinib

Speaking from the 23rd Congress of the European Hematological Association (EHA) 2018 in Stockholm, Sweden, Naval Daver, MD, of the MD Anderson Cancer Center, Houston, TX, speaks about three new target... Author: VJHemOnc Added: 07/31/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts